Vitamin D and Breast Cancer

Vitamin D

Volumn 2, Issue , 2005, Pages 1663-1677

  Colston, Kay ^a   Welsh, Joellen ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 30344483447     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012252687-9/50097-8     Document Type: Chapter

References (142)

1. Colston KW, Mork Hansen C Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocrine Related Cancer 2001, 9:45-59.
2. 3 and its analogs on growth control and tumorigenesis. Frontiers in Biosci 2001, 6:820-848.
3. Mehta RG, Mehta RJ Vitamin D and cancer. J Nutr, Biochem 2002, 13:252-264.
4. 3 and its analog EB1089 in human breast cancer cells. Oncogene 1997, 15:1555-1563.
5. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 cells. Breast Cancer Res Treat 1997, 42:31-41.
6. 3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest 1995, 13:280-286.
7. 3 and its analogs on induction of apoptosis in breast cancer cells. J Steroid Biochem Molec Biol 1996, 58:395-401.
8. Mørk Hansen C, Rhode L, Madsen MW, Hansen D, Colston KW, Pirianov G, Holm PK, Binderup L MCF-7/VDR: a new vitamin D-resistant cell line. J Cell Biochem 2001, 82:422-436.
9. Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh JE Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 2003, 84:181-192.
10. 3 leads, to the induced differentiation of the myelocytic cell line U937. Genes & Development 1996, 10:142-153.
11. Jensen S, Madsen MW, Lukas J, Binderup L, Bartek J Inhibitory effects of 1α,25-dihydroxyvitamin D3 on the G1-S phase controlling machinery. Mol Endocrinol 2001, 15:1370-1380.
12. 3 on the cell cycle genes, cyclin D1, p21, and p27 in MCF-7 cells. Mol Cell Endocrinology 1998, 142:57-65.
13. Inoue T, Kamiyama J, Sakai T Sp1 and NF-Y synergistically, mediate the effect of vitamin D(3) in the p27(kip 1) gene promoter that lacks vitmin D response elements. J Biol Chem 1999, 274:32309-32317.
14. Bettoun DJ, Buck DW, Lu J, Khalifa B, Chin WW, Nagpal S A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J Biol Chem 2002, 277:24847-24850.
15. 5 in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer 2000, 36:780-786.
16. Mathiasen IS, Colston KW, Binderup L EB1089, a novel vitamin D analog, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Molec Biology 1993, 46:365-371.
17. 3 and retinoic acid analogues induce differentiation, in breast cancer cells with function and cell specific additive effects. Breast Cancer, Research Treat 2001, 67:157-168.
18. 3 on human thyroid cancer cell growth. Endocrine J 1999, 46:243-252.
19. James SY, Mackay AG, Colston KW Vitamin D derivatives in combination with 9- cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 1995, 14:391-394.
20. Elstner E, Linker-Israli M, Said J, Umiel T, deVos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP 20-epi-vitamin D analogs: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Research 1995, 55:2822-2830.
21. 3-resistant variant. Endocrinolgy 1997, 138:4690-4698.
22. 3 on cell cycle kinetics of T47D human breast cancer cells. J Cell Physiol 1989, 138:611-616.
23. Mathiasen IS, Lademann U, Jäättelä M Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Research 1999, 59:4848-4856.
24. 3 actions in human breast cancer cells. J Steroid Biochem Mol Biol 2003, 84:149-157.
25. 3 on breast and prostate cells are associated with induction, of BRCA1 gene expression. Oncogene 2000, 19:5091-5097.
26. James SY, Mackay AG, Binderup L, Colston KW Effects of a new synthetic vitamin D analog, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinology 1994, 141:555.
27. 3 derivatives and breast cancer. Schering Foundation Workshop 1995, Volume 14:201-224. Springer Verlag, Heidelberg. M. Tenniswood, H. Michna (Eds.).
28. 3 down-regulates estrogen receptor adundance and suppresses estrogen action in MCF-7 human breast cancer cells. Clin Cancer Research 2000, 6:3371-3379.
29. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, mock Nauta RJ, Evans SR Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 1994, 31:191-202.
30. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K Anti-tumor effect of 22-oxa-calctriol, a noncalcemic analog of calcitriol in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Research 1993, 53:2534-2537.
31. Vink-van Wijngaarden T, Pols HAP, Buurman CJ, van der Bemd GJCM, Dorssers CJ, Birkenhager JC, van Leeuwen JPTM Inhibition of breast cancer cell growth by combined treatment with vitamin D analogs and tamoxifen. Cancer Research 1994, 54:5711-5717.
32. 3 analogs in breast cancer cells. Cancer Research 1996, 56:2789-2794.
33. 3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells. Mol Cell Biochem 1998, 188:13-20.
34. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenester BD, Martin MB Regulation of estrogen receptorα gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 1999, 75:640-651.
35. 3 in breast cancer cells occur at the estrogen response element level but through different mechanisms. Cancer Research 1994, 54:1458-1464.
36. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991, 129:832-837.
37. Colston KW, Perks CM, Xie SP, Holly JMP Growth inhibition of both MCF-7, and Hs578T human breast cancer cell lines by vitamin, D analogs is associated with increased expression of insulin-like binding protein-3. J Mol Endocrinol 1998, 20:157-162.
38. Xie SP, Pirianov G, Colston KW Vitamin D analogs suppress IGF-I signaling and promote apoptosis in breast cancer, cells. Eur J Cancer 1999, 35:1717-1723.
39. Flanagan L, Van Weelden K, Ammerman C, Ethier S, Welsh JE SUM-159PT cells, a novel estrogen independent human breast cancer model system. Breast Cancer Research Treat 1999, 58:193-204.
40. Larsen SS, Heiberg I, Lykkesfeldt AE Anti-estrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analog EB 1089 than parent MCF-7 cells. Br J Cancer 2001, 84:686-690.
41. 3 on the growth of human colonic and breast carcinoma. Vitamin D, a Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology, and Clinical Applications 1994, 469-476. De Gruyter, Berlin. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
42. Desprez P-Y, Poujol D, Falette N, Lefebvre M-F, Saez F 1,25-dihydroxyvitamin D3 increases epidermal growth factor receptor gene expression in BT-20 breast carcinoma cells. Biochem Biophys Res Comm 1991, 176:1-6.
43. 3 in human breast cancer cells. Cancer Research 1988, 48:2734-2739.
44. 3 target gene in squamous cell and breast carcinoma. Biochem Biophys Res Commun 2001, 281:1051-1056.
45. Sachdev D, Yee D The IGF system and breast cancer. Endocr Relat Cancer 1994, 8:197-209.
46. Rozen F, Yang X-F, Huynh H, Pollak M Antiproliferative action of vitamin D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 1997, 89:652-656.
47. 3 and the vitamin D analog EB1089. Eur J Cancer 1996, 32A:842-848.
48. Xie S, James SY, Colston KW Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 1997, 154:495-504.
49. Pirianov G, Colston KW Interaction of vitamin D analogs with signaling pathways leading to apoptosis in breast cancer cells. Steroids 2001, 66:309-318.
50. 3 has been shown to enhance the expression of transforming growth factor B1 and its latent form binding protein in breast carcinoma cells. Cancer Research 1994, 55:1540-1547.
51. Mercier T, Chaumontet C, Gaillard-Sanchez I, Martel P, Heberden C Calcitriol and lexicalcitol (KH1060) inhibit the growth of human breast adenocarcinoma cells by enhancing transforming growth factor- production. Biochem Pharmacol 1996, 52:505-510.
52. Wu Y, Craig TA, Lutz WH, Kumar R Identification of vitamin D response elements in the human transforming growth factor beta 2 gene. Biochemistry 1999, 38:2654-2660.
53. 3: coordinate regulator of active cell death and proliferation in MCF-7 breast cancer cells. Schering Foundation Workshop 1995, Volume 14:191-200. Springer Verlag, Heidelberg. M. Tenniswood, H. Michna (Eds.).
54. 3 analoginduced growth inhibition in breast cells. J Cell Physiol 2001, 188:383-393.
55. Welsh JE Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 1994, 72:537-545.
56. 3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996, 58:367-376.
57. 3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Research 2000, 60:2040-2048.
58. Pirianov G, Colston KW Interactions of vitamin D analog CB1093, TNFa, and ceramide on breast cancer cell apoptosis. Mol Cell Endocrinol 2001, 172:69-78.
59. Sundaram S, Sea A, Feldman S, Strawbridge R, Hoopes PJ, Demidenko E, Binderup L, Gewirtz DA The combination of a potent vitamin D analog, EB1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Research 2003, 9:2350-2356.
60. Narvaez CJ, Welsh JE Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001, 276:9101-9107.
61. 3-resistant variant can be sensitized by TPA. J Steroid Biochem Mol Biol 2003, 84:199-209.
62. Scorrano L, Korsmeyer SJ Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Comm 2003, 304:437-444.
63. Weitsman GE, Ravid A, Liberman U, Koren R Vitamin D enhances caspase dependent and independent TNF α induced breast cancer cell death: the role of reactive oxygen species and mitochondria. Int J Cancer 2003, 106:178-186.
64. 3 compounds in breast cancer cells. J Biol Chem 2003, 277:30738-30745.
65. 3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994, 12:195-202.
66. 3 and its analogs down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth and Differentiation 2000, 11:221-229.
67. 3 analogs. Eur J Pharmacol 1990, 178:247-250.
68. 3 is a potent inhibitor of tumor cell-induced angiogenesis. J Invest Dermatol Symp Proc 1996, 1:97-101.
69. Matsumoto H, Lino Y, Koibuchi Y, Andoh T, Horii Y, Takei H, Horiguchi J, Maemura M, Yokoe T, Morishita Y Antitumor effect of 22-oxacalcitriol on estrogen receptor negative MDA-MB-231 tumors in athymic mice. Oncol Rep 1999, 6:349-352.
70. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Research 2000, 87:214-220.
71. 3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989, 83:1903-1915.
72. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL Antiproliferative effect of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143:2508-2514.
73. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nature Genetics 2001, 25:144-146.
74. 3-1α-hydroxylase in breast tissue. Vitamin D endocrine system: Structural, Biological, Genetic and Clinical Aspects 2000, 189-191. University of California Riverside Press, Riverside, CA. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
75. 3 receptor on growth regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 2003, 83:85-92.
76. 3. Clin Endocrinology 1980, 13:267-272.
77. 3 binding in estrogen responsive rat breast tumor. Endocrinology 1986, 119:397-403.
78. Zinser GM, McEleney K, Welsh JE Characterization of mammary tumor cell lines from wild-type and vitamin D receptor knockout mice. Mol Cell Endocrinology 2003, 200:67-80.
79. 3 receptor gene expression in cultured cells by serum and growth factors. J Bone Mineral Research 1991, 6:1099-1107.
80. 3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Research Treat 1999, 54:123-133.
81. 3 receptor as target for breast cancer prevention. J Nutrition 2003, 133:2425S-2433S.
82. 3-resistant MCF-7 cell line. Endocrinology 1996, 137:400-409.
83. Byrne I, Flanagan L, Tenniswood M, Welsh JE Identification of a hormone responsive promoter immediately upstream of exon 1 c in the human vitamin D receptor gene. Endocrinology 2000, 141:2829-2836.
84. Agadir A, Lazzara G, Zheng Y, Zhang X, Mehta RG Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis 1999, 20:577-582.
85. VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh JE Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D analog EB1089. Endocrinology 1998, 139:2102-2110.
86. 3 receptors in breast cancer and relationship to biochemical and clinical indices. Cancer Research 1984, 44:1677-1681.
87. 3 receptor in primary breast cancers. Cancer Research 1986, 46:5406-5408.
88. 3 receptor in primary breast cancer. Cancer Research 1987, 47:6793-6795.
89. Friedrich M, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrat J, Axt-Fliedner R Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res 2002, 22:1919-1924.
90. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrat J Analysis of vitamin D receptor (VDR) and retinoid X receptor alpha in breast cancer. Histochem J 2002, 34:35-40.
91. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC Immunocytochemical detection of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relation to prognosis. Cancer Research 1991 1991, 51:239-244.
92. Colston KW, Berger U, Coombes RC Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989, 1:185-191.
93. Colston KW, Chander SK, Mackay AG, Coombes RC Effects of synthetic vitamin D analogs in breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992, 44:1153-1155.
94. Binderup L, Bramm E Effects of a novel vitamin D analog MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988, 37:887-895.
95. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC EB 1089: a new vitamin D analog that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 1992, 44:2273-2280.
96. Bower M, Colston KW, Stein RC, Hedley A, Gazet J-C, Ford HT, Coombes RC Topical calcipotriol treatment in advanced breast cancer. Lancet 1991, 337:701-702.
97. Andoh T, Lino Y Usefulness of 22-oxa-1,25-dihydroxyvitamin D3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Int J Oncology 1996, 9:79-82.
98. Mørk Hansen C, Hamberg KJ, Binderup E, Binderup L Seocalcitol (EB1089): a vitamin D analog of anti-cancer potential. Background, design, synthesis, preclinical, and clinical evaluation. Curr Pharmaceut Des 2000, 6:803-828.
99. Mackay AG, Ofori-Kuragu EA, Lansdown A, Coombes RA, Binderup L, Colston KW Effects of the synthetic vitamin D analog EB1089 and tamoxifen on the growth of experimental rat mammary tumors. Endocrine Related Cancer 1996, 3:327-335.
100. 3, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 1998, 125:953-962.
101. 3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Research Treatment 1999, 53:113-120.
102. Koshizuka K, Kubota T, Said J, Koike M, Binderup L, Uskokovic M, Koeffler HP Combination therapy of a vitamin D analog and all trans retinoic acid. Effect on human breast cancer in nude mice. Anticancer Research 1999, 19:519-524.
103. El Abdaimi K, Dion N, Papavasiliou V, Cardinal P-E, Binderup L, Goltzman D, Ste-Marie L-G, Kremer R The vitamin D analog EB1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Research 2000, 60:4412-4418.
104. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC A phase I study of the vitamin D analog EB1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998, 78:6-13.
105. Uskokovic MR, Studzinski GP, Gardner JP, Reddy SG, Campbell MJ, Koeffler HP The 16-ene vitamin D analogs. Curr Pharmaceut Des 1997, 3:99-123.
106. 3: a novel class of potent inhibitors of proliferation of human breast cell lines. Cancer Research 1997, 57:4545-4550.
107. 3 analog shows relation to promoter selectivity. J Cell Biochem 1997, 66:552-562.
108. 3 analog (CB 1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol 1998, 13:421-428.
109. Verlinden L, Verstuyf A, van Camp M, Marcelis S, Sabbe K, Zhao X-Y, de Clercq P, Vandewalle M, Bouillon R Two novel 14-epi analog of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Research 2000, 60:2673-2679.
110. Hussain EA, Mehta RR, Ray R, Das Gupta TK, Mehta RG Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy. Recent Results Cancer Res 2003, 164:393-411.
111. 3 receptors in human breast cancer cell lines. Cancer Research 1980, 40:4764-4767.
112. 3 target cells in rat mammary gland. Horm Res 1981, 15:263-269.
113. 3 receptor ablation alters mammary gland morphogenesis. Development 2002, 129:3067-3076.
114. 3 receptor content during pregnancy and lactation. Mol Cell Endocrinology 1988, 60:15-22.
115. Mezzetti G, Barbiroli B, Oka T 1,25-dihydroxycholecalciferol receptor regulation in hormonally-induced differentiation of mouse mammary gland in culture. Endocrinology 1987, 120:2488-2493.
116. Kanazawa T, Enami J, Hohmoto K Effects of 1 alpha, 25-dihydroxycholecalciferol and cortisol on the growth and differentiation of primary cultures of mouse mammary epithelial cells in collagen gel. Cell Biology International 1999, 23:481-487.
117. 3 in mammary gland: from normal development to breast cancer. Steroids 2001, 66:301-308.
118. Bhattacharjee M, Wientroub S, Wonderhaar BK Milk protein synthesis by mammary glands of vitamin D-deficient mice. Endocrinology 1987, 121:865-874.
119. Mezzetti G, Monti M, Casolo L, Piccinini G, Moruzzi M 1,25-dihydroxycholecalciferol-dependent calcium uptake by mouse mammary gland in culture. Endocrinology 1988, 122:389-394.
120. Jacobson E, James K, Newmark H, Carroll K Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Research 1989, 49:6300-6303.
121. Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB 1α-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analog) for prevention of breast cancer in the rat. Cancer Research 1994, 54:1653-1656.
122. Mehta R, Hawthorne M, Uselding L, Albinescu D, Moriarty R, Christov K, Mehta R Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1α-hydroxyvitamin D5. J Natl Cancer Inst 2000, 92:1836-1840.
123. Mehta R, Moriarty R, Mehta R, Penmasta R, Lazzaro G, Constantinou A, Guo L Prevention of preneoplastic mammary lesion development by a novel vitamin D analog, 1α-hydroxyvitamin D5. J Natl Cancer Inst 1997, 89:212-218.
124. Knekt P, Jarvinen R, Seppanen R, Pukkala E, Aromaa A Intake of dairy products and risk of breast cancer. Br J Cancer 1996, 73:687-691.
125. Shin MJ, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst. 2002, 94:1301-1310.
126. John EM, Schwartz GG, Dreon DM, Koo J Vitamin D and breast cancer risk: the NHA NES I epidemiologic follow-up study, 1971-1975 to 1992. Cancer Epidemiol Biomarkers Prev 1999, 8:399-406.
127. Garland FC, Garland CF, Gorham ED, Young JF Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990, 19:614-622.
128. Freedman DM, Dosemeci M, McGlynn K Sunlight and mortality from breast, ovarian, colon, prostate, and nonmelanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 2002, 59:257-262.
129. Grant WB An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002, 94:272-281.
130. Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endo Metab 1997, 82:118-122.
131. 3 and breast cancer risk. Pub Health Nutr 1999, 2:283-291.
132. Curran JE, Vaughn T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR Association of a vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 1999, 83:723-726.
133. Yamagata Z, Zhang Y, Asaka A, Kanamori M, Fukutomi T Association of breast cancer with vitamin D receptor gene. Am J Hum Genet 1997, 61:388.
134. Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colson KW Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 2001, 85:171-176.
135. Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healy CS, Smith N, Pharoah PDP, Luben RN, Easton DF, Ponder BAJ No association between androgen or vitamin D receptor gene polymorphisms and breast cancer. Carcinogenesis 1999, 20:2131-2135.
136. Newcomb PA, Kim H, Trentham-Dietz A, Farin F, Hunter DKM Vitamin D receptor polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:1503-1504.
137. Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Coetzee GA Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Contr 2000, 11:25-30.
138. Hou MF, Tien YC, Lin GT, Chen CJ, Liu CS, Lin SY, Huang TJ Association of vitamin D receptor gene polymorphisms with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 2002, 74:1-7.
139. Ruggiero M, Pacini S, Aterini S, Allai C, Ruggiero C, Pacini P Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncology Research 2001, 10:43-46.
140. Lundin AC, Soderkvist P, Eriksson B, Bergmann-Jungestrom M, Wingren S Association of breast cancer progression with a vitamin D receptor polymorphism. Cancer Research 1999, 59:2332-2334.
141. Schondorf T, Eisberg C, Wassmer G, Warm M, Becker M, Rein DT, Gohring UJ Association of the vitamin D receptor genotype with bone metastases in breast cancer patients. Oncology 2003, 64:154-159.
142. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, Haussler CA, Galligan MA, Thatcher ML, Encinas Dominguez C, Haussler MR Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001, 177:45-59.